` SGMT (Sagimet Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

SGMT
vs
S&P 500

Over the past 12 months, SGMT has significantly outperformed S&P 500, delivering a return of +205% compared to the S&P 500's +13% growth.

Stocks Performance
SGMT vs S&P 500

Loading
SGMT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
SGMT vs S&P 500

Loading
SGMT
S&P 500
Difference
www.alphaspread.com

Performance By Year
SGMT vs S&P 500

Loading
SGMT
S&P 500
Add Stock

Competitors Performance
Sagimet Biosciences Inc vs Peers

S&P 500
SGMT
ABBV
AMGN
GILD
VRTX
Add Stock

Sagimet Biosciences Inc
Glance View

Market Cap
303m USD
Industry
Biotechnology

Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

SGMT Intrinsic Value
Not Available
Back to Top